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objective quality of life mean change scale scores, using
the QOLIE-31, for similar constructs in a 3-month study
of add-on therapy in 329 refractory epilepsy patients ex-
periencing partial seizures. The validity and responsive-
ness of the QOL transition scales, the QOLIE-31 scales,
compliance and treatment satisfaction scales were also
examined. RESULTS: Correlations between the QOL
transition scales and QOLIE-31, satisfaction and compli-
ance mean change scores were significant but low to
moderate (0.10–0.39) for the majority of scales. The QO-
LIE-31 worry scale and the treatment satisfaction scale
proved to be the most responsive to clinical changes. The
transition scales, however, often indicated that respond-
ers perceived significantly more improvement than non-
responders, particularly for change in social life and glo-
bal QOL. CONCLUSIONS: These results suggest that
measuring patients’ perception of change in QOL is not
the same as measuring change in QOL objectively (i.e.
over time). Perceptions appear to play an important role
in patients’ satisfaction with and willingness to continue
treatment. In addition, patients’ perceptions of treatment
and its effect on their lives appear sensitive to short-term
treatment. These changes may, however, be distinct from
those QOL domains that change with sustained control
of seizures. Further research into patient satisfaction and
perceptions of QOL change, particularly in short-term
epilepsy trials, may be valuable in refining measurement
methodology.
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OBJECTIVE: Clinical studies show that entacapone sig-
nificantly increases ON time. Increases in ON time are
associated with decreases in resource utilization. This
study is designed to examine the cost-effectiveness of
usual care with entacapone versus usual care without en-
tacapone in patients with Parkinson’s disease. The setting
for this study was The Netherlands. METHODS: A
Markov process model was constructed to model the av-
erage quality adjusted life years (QALYs) and the costs of
both treatments. The 5-year model captured the impact
of treatment on symptoms and disease progression. Data
for the construction of the model were derived from pub-
lished literature, including large multicenter randomized
clinical trials in patients with end-of-dose wearing off.
Costs were obtained primarily from published sources.
RESULTS: The results of the baseline analysis showed a
slight decrease of the 5-year total average discounted
costs from NLG 111,317 to NLG 110,038, resulting in
an effectiveness increase in the entacapone arm from 2.42
to 2.56 quality-adjusted life years (QALYs), a 6% in-
crease. In addition, entacapone substantially increased
“time in which patients are able to perform everyday ac-
tivities” by 0.63 years. Sensitivity analyses confirmed the
robustness of these findings. CONCLUSION: Entaca-
pone is a cost-effective treatment, yielding improvement
in terms of both effectiveness measures (time without se-
vere fluctuations and QALYs), without additional cost
when compared to PD treatment w/o entacapone. The
additional drug costs for entacapone are offset by reduc-
tions in other costs, especially hospitalization. 
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OBJECTIVES: To adapt a previously published US-based
model for economic evaluation of the fentanyl transder-
mal system and controlled-release oral morphine, for the
control of moderate to severe chronic pain, for use in
Canada. METHODS: A panel of Canadian experts con-
firmed the model’s clinical validity and provided esti-
mates of medical resource utilization to treat various
model events. We applied Canadian unit costs to these
estimates. We populated the model with the results from
a randomized cross-over trial of the fentanyl transdermal
system compared to oral morphine in patients with
chronic moderate to severe nonmalignant pain. We used
the adapted model to assess the incremental cost-utility
of the fentanyl transdermal system compared to con-
trolled-release morphine in Canadian patients with chronic
nonmalignant pain. RESULTS: The results of the Cana-
dian and US analyses were similar. Because Canada and
the US use different medical resources used to treat
events, the average total costs to treat opioid use-related
events decreased and were distributed differently. The
newly available event rates were similar to those used in
the U.S. model, which were pulled from disparate data
sources or estimated by clinical experts. In the Canadian
model, the incremental cost-utility ratio of the fentanyl
transdermal system compared to controlled-release oral
morphine is CAN$17,354 (compared to US$20,709). The
primary cost drivers are the cost of the opioid medica-
tions themselves, the use of rescue pain medication, and
the rate of discontinuation from the initial opioid ther-
apy. CONCLUSIONS: The incremental cost-utility of the
fentanyl transdermal system compared to controlled-re-
lease oral morphine does not change substantially when
evaluated using Canadian parameter estimates.
